Vyloy

Vyloy is a cancer medicine that is used to treat adults with gastric or gastro-oesophageal junction adenocarcinoma (a type of cancer of the stomach or the transition between the stomach and oesophagus). It is used in combination with chemotherapy when the cancer is locally advanced (has spread nearby) and cannot be removed by surgery or when it is metastatic (has spread to other parts of the body). Vyloy can be used when the cancer cells are HER2 negative and Claudin (CLDN) 18.2 positive; this means they do not have large quantities of the HER2 receptor (target) on their surface but do have a large number of the CLDN18.2 protein. Gastric and gastro-oesophageal adenocarcinoma are rare, and Vyloy was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 26 November 2010. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-803). Vyloy contains the active substance zolbetuximab.